First Line Therapy for High Risk Acute GVHD
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE2
Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy
- Status
- UNKNOWN
- Phase
- N/A
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
- Status
- RECRUITING
- Phase
- PHASE2
Ruxolitinib Combined With Dexamethasone for HLH
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
- Status
- UNKNOWN
- Phase
- PHASE2
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2